HRP20211817T1 - Postupak adjuvantnog liječenja raka - Google Patents
Postupak adjuvantnog liječenja raka Download PDFInfo
- Publication number
- HRP20211817T1 HRP20211817T1 HRP20211817TT HRP20211817T HRP20211817T1 HR P20211817 T1 HRP20211817 T1 HR P20211817T1 HR P20211817T T HRP20211817T T HR P20211817TT HR P20211817 T HRP20211817 T HR P20211817T HR P20211817 T1 HRP20211817 T1 HR P20211817T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination
- use according
- patient
- dabrafenib
- trametinib
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960002465 dabrafenib Drugs 0.000 claims 8
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 8
- 229960004066 trametinib Drugs 0.000 claims 8
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 6
- 230000004083 survival effect Effects 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 238000002271 resection Methods 0.000 claims 2
- 208000037981 stage III cutaneous melanoma Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696375P | 2012-09-04 | 2012-09-04 | |
| EP13835019.4A EP2892535B1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
| PCT/US2013/057432 WO2014039375A1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211817T1 true HRP20211817T1 (hr) | 2022-03-04 |
Family
ID=50237545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211817TT HRP20211817T1 (hr) | 2012-09-04 | 2013-08-30 | Postupak adjuvantnog liječenja raka |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20150216868A1 (enExample) |
| EP (2) | EP3981408A1 (enExample) |
| JP (3) | JP2015527374A (enExample) |
| KR (1) | KR102134585B1 (enExample) |
| CN (2) | CN107308164A (enExample) |
| AU (2) | AU2013313050A1 (enExample) |
| BR (1) | BR112015004578A2 (enExample) |
| CA (1) | CA2882437C (enExample) |
| CY (1) | CY1124812T1 (enExample) |
| DK (1) | DK2892535T3 (enExample) |
| ES (1) | ES2900825T3 (enExample) |
| HR (1) | HRP20211817T1 (enExample) |
| HU (1) | HUE056646T2 (enExample) |
| IN (1) | IN2015KN00449A (enExample) |
| LT (1) | LT2892535T (enExample) |
| PL (1) | PL2892535T3 (enExample) |
| PT (1) | PT2892535T (enExample) |
| RU (1) | RU2640180C2 (enExample) |
| SI (1) | SI2892535T1 (enExample) |
| WO (1) | WO2014039375A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2892535T3 (da) | 2012-09-04 | 2022-01-03 | Novartis Ag | Fremgangsmåde til adjuverende cancerbehandling |
| ES2784450T3 (es) | 2013-12-28 | 2020-09-25 | Guardant Health Inc | Métodos y sistemas para detectar variantes genéticas |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| EP4272740A1 (en) * | 2017-05-02 | 2023-11-08 | Novartis AG | Combination therapy comprising a raf inhibitor and trametinib |
| WO2019204399A1 (en) * | 2018-04-17 | 2019-10-24 | The University Of Chicago | Methods and compositions for treating cancer |
| CN109106893B (zh) * | 2018-11-12 | 2021-04-20 | 上海市中西医结合医院 | 一种调节肠道屏障功能的中药复方制剂及其制备方法 |
| JP2022531969A (ja) | 2019-05-13 | 2022-07-12 | ノバルティス アーゲー | 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態 |
| CN118767143A (zh) * | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| EP4444299A1 (en) | 2021-12-06 | 2024-10-16 | My Personal Therapeutics Ltd | A combination treatment for cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005004286T2 (de) * | 2004-06-11 | 2009-01-02 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs |
| KR20190062506A (ko) * | 2005-02-18 | 2019-06-05 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| MY174759A (en) * | 2009-10-16 | 2020-05-13 | Novartis Ag | Pharmaceutical combination of mek inidbitor and b-raf inhibitors |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| DK2892535T3 (da) | 2012-09-04 | 2022-01-03 | Novartis Ag | Fremgangsmåde til adjuverende cancerbehandling |
-
2013
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active Active
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en not_active Ceased
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
-
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
-
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
-
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
-
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
-
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
-
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
-
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211817T1 (hr) | Postupak adjuvantnog liječenja raka | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| JP2010222367A5 (enExample) | ||
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| ECSP11011324A (es) | 3h-imidazo[4,5-c]piridina-6-carboxamidas en calidad de agentes antiinflamatorios | |
| PE20151156A1 (es) | Tratamientos de combinacion para melanoma que comprenden la administracion de cobimetinib y vemurafinib | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2014505733A5 (enExample) | ||
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| MY177741A (en) | Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate. | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2015527374A5 (enExample) | ||
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| ZA201404068B (en) | The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents |